Antibiotics

New vancomycin dosing regimens are proposed to improve outcome and minimize toxicity in overweight and obese patients with renal insufficiency.

New challenges in the fight against gonorrhea in the US.

Emerging treatment options for patients with persistently positive blood cultures with Methicillin-Susceptible Staphylococcus aureus (MSSA).

How the development of antimicrobial stewardship programs can be an effective strategy for beginning to reduce this critical timing for patients in ICUs.

Doxycycline postexposure prophylaxis (PEP) has reduced STIs among men who have sex with men, but poor adherence marred trial results with women.

Investigators studying over 4500 patients with gram-negative bacteremia see opportunities for earlier transition from IV to oral antibiotics.

This year saw the approval of new therapies as well as the continued evolution of time-to-treat infections and updated guidelines.

The current treatment pathway might need to evolve to adjust to rapid diagnostics and narrowing down the antibiotics to aid in optimal outcomes for sicker patients with gram-negative infections.

Three posters presented at ASHP Midyear 2023 delved deeper into the topic of antimicrobial stewardship programs and their impact on antibiotic resistance.

Recent studies support the argument that all positive blood cultures trigger an automatic consultation.

Investigators asked the children’s parents about the history of musculoskeletal-related disease, observed the children’s gait, and performed physical examinations.

This bipartisan initiative highlights the need for a comprehensive approach to combat antimicrobial resistance (AMR), incorporating both antibiotic drug development and increased funding for stewardship programs.

Amikacin inhaled once daily for 3 days reduced risk of developing ventilator-associated pneumonia in placebo-controlled trial in critically ill.

A recent novel study found reduced mortality rates in combining these therapies in patients being treated for this specific bacteremia.

A study showed utilizing a PCR-based test can narrow therapy quicker and help in resolving these infections sooner.

The implementation of new College of American Pathologists rules presents an opportunity for collaboration between clinical microbiology laboratories and infectious disease pharmacists and physicians.

A small study showed high efficacy for the same strain of Pseudomonas aeruginosa.

The proposed clinical benefits of de-escalation has contributed to its lukewarm adoption in some settings. This article looks at the challenges in measuring the impact of de-escalation, and the ongoing search for more meaningful metrics to evaluate the success of antimicrobial stewardship (AMS) programs.

The investigational agent, afabicin, was developed by private company, Debiopharm, and a clinician offers some insights on the therapy in these 2 therapeutic areas.

Empirical antibiotic therapy in diabetic foot ulcer infections increases hospitalization and prolonged symptoms in patients being treated for lower limb cellulitis are common. Two recent papers examine the need for effective communication, the importance of objective findings in cellulitis management, and the benefits of culture-based antibiotic therapy in diabetic foot ulcer cases.

Although the current reimbursement model makes it difficult for pharmaceutical companies to recoup their investments, a subscription model like the prospective congressional bill, the Pasteur Act, may help change that paradigm. In addition, there are international measures being carried out that may bring about changes.

The companies announced a licensing agreement on cefepime-taniborbactam.

S salivarius probiotic reduces relative abundance of nasopharyngeal otopathogens but not incidence of acute otitis media in children.

This form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.

A new study highlights the growing threat of drug-resistant pathogens, particularly in healthcare settings, and underscores the need for enhanced surveillance and intervention strategies to combat these emerging and resistant infectious diseases.